Pharmacokinetics and efficacy of Vedolizumab in inflammatory bowel diseases

Not Applicable

Suspended

• Conditions: s disease; ulcerative colitis and Crohn&#39

• Registration Number: JPRN-UMIN000045425
• Lead Sponsor: Shiga University of Medical Science

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-09-08
• Study Completion: 2023-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Suspended
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

none

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical remission at 30 weeks from the start of administration